Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.52 |
| ▸ | CTSK | P43235 | 3/20 | 0.52 |
| ▸ | REN | P00797 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 7/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18946401 | 0.90 | CTSS (0.50) | CTSSCTSKRENCA2BACE1 | |
| SCHEMBL17109077 | 0.89 | CTSK (0.50) | CTSSCTSKRENCA2BACE1 | |
| SCHEMBL18946399 | 0.84 | CA1 (0.44) | CTSSCTSKCA2 | |
| SCHEMBL10144023 | 0.81 | CTSS (0.59) | CTSSCTSKRENCA2BACE1 | |
| SCHEMBL18946400 | 0.81 | CTSK (0.43) | CTSSCTSKRENCA2BACE1 | |
| SCHEMBL18946433 | 0.79 | CTSK (0.42) | CTSSCTSKCA2 | |
| SCHEMBL18946365 | 0.79 | CTSK (0.42) | CTSSCTSKCA2 | |
| SCHEMBL30064531 | 0.79 | CTSS (0.63) | CTSSCTSKRENCA2BACE1 | |
| SCHEMBL17109090 | 0.78 | CTSK (0.41) | CTSSCTSKRENCA2 | |
| SCHEMBL29918073 | 0.78 | CTSS (0.56) | CTSSCTSKRENCA2BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9969758-B2 | Antimicrobial compounds | BIOMERIEUX (FR) | 2018-05-15 | — | — | US | disclosed |
| US-20170158720-A1 | Antimicrobial Compounds | BIOMERIEUX (FR) | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158720-A1 | Antimicrobial Compounds | NGLY1, MRPL21, VIP | CTSS 1214/4885CTSK 1125/4885REN 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.